Perrigo Company plc (NYSE:PRGO) Receives Consensus Rating of “Hold” from Analysts

Perrigo Company plc (NYSE:PRGOGet Free Report) has earned an average rating of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $19.3333.

A number of research analysts have recently weighed in on PRGO shares. Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings raised Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th.

Check Out Our Latest Stock Report on PRGO

Perrigo Trading Down 1.5%

Perrigo stock traded down $0.20 during mid-day trading on Friday, hitting $13.28. The stock had a trading volume of 172,532 shares, compared to its average volume of 3,072,589. The stock has a 50-day simple moving average of $12.55 and a two-hundred day simple moving average of $11.39. The company has a current ratio of 2.32, a quick ratio of 1.32 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $1.84 billion, a PE ratio of -1.06, a P/E/G ratio of 1.55 and a beta of 0.59. Perrigo has a 12 month low of $9.23 and a 12 month high of $22.65.

Perrigo (NYSE:PRGOGet Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm earned ($0.06) EPS. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts forecast that Perrigo will post 2.18 EPS for the current year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 15th. Investors of record on Friday, August 28th were paid a dividend of $0.29 per share. The ex-dividend date of this dividend was Friday, August 28th. This represents a $1.16 annualized dividend and a yield of 8.7%. Perrigo’s dividend payout ratio (DPR) is presently -9.27%.

Institutional Investors Weigh In On Perrigo

Several hedge funds have recently bought and sold shares of PRGO. EverSource Wealth Advisors LLC raised its stake in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares during the period. Huntington National Bank grew its holdings in shares of Perrigo by 99.9% during the fourth quarter. Huntington National Bank now owns 4,741 shares of the company’s stock worth $66,000 after buying an additional 2,369 shares in the last quarter. KBC Group NV raised its position in Perrigo by 61.3% in the 1st quarter. KBC Group NV now owns 6,283 shares of the company’s stock valued at $67,000 after buying an additional 2,388 shares during the last quarter. Parvin Asset Management LLC bought a new stake in Perrigo in the 2nd quarter valued at approximately $79,000. Finally, Allworth Financial LP lifted its stake in Perrigo by 489.1% in the 2nd quarter. Allworth Financial LP now owns 9,390 shares of the company’s stock valued at $98,000 after acquiring an additional 7,796 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

About Perrigo

(Get Free Report)

Perrigo Company plc is a global consumer self-care company that develops, manufactures and markets over-the-counter (OTC) products and other nonprescription health and wellness products. Its portfolio spans consumer health categories including pain relief, allergy and cold remedies, digestive health, skin care, oral care, vitamins and supplements, and women’s health.

The company sells products under both its own brands and retailer-owned store brands through pharmacies, supermarkets, mass merchants, e-commerce channels and other outlets.

Read More

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.